| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0007 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0007 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0008 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.16 | 0.001 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |